Table 4.
Country | Ref. | Publication | Treatment duration | Patients | Therapy regimen | Eradication rate (ITT) | Eradication rate (PP) |
South Korea | Choi et al[189] | 2011 | 7 d | 98 | Ome 20 mg bid | 65.3% | 73.6% |
Lev 200 mg bid | |||||||
Amo 1 g bid | |||||||
China | Liao et al[122] | 2013 | 14 d | 81 | Lan 30 mg bid | 82.7% | 85.9% |
Lev 500 mg qd | |||||||
Amo 1 g bid | |||||||
Taiwan | Liou et al[190] | 2010 | 7 d | 217 | Lan 30 mg bid | 74.2% | 80.1% |
Lev 750 mg qd | |||||||
Amo 1 g bid | |||||||
Chen et al[117] | 2014 | 7 d | 73 | Rab 20 mg bid | 78.1% | 80.9% | |
Lev 500 mg bid | |||||||
Amo 1 g bid | |||||||
Spain | Molina-Infante et al[114] | 2010 | 10 d | 115 | Ome 20 mg bid | 80.8% | 82.6% |
Lev 500 mg bid | |||||||
Amo 1 g bid |
ITT: Intention to treat; PP: Per protocol; Lan: Lansoprazole; Lev: Levofloxacin; Amo: Amoxicillin; Rab: Rabeprazole; Eso: Esomeprazole; Cla: Clarithromycin; Ome: Omeparzole.